Cited by 501Nanoplatforms for cancer theranosticsNanoparticle-Based Drug DeliveryNanotechnology research and applications

Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine

Open access
Adir, Omer, Poley, Maria, Chen, Gal, Froim, Sahar, Krinsky, Nitzan, Shklover, Jeny, Shainsky‐Roitman, Janna, Lammers, Twan +1 more·2020·Advanced Materials

Abstract

Artificial intelligence (AI) and nanotechnology are two fields that are instrumental in realizing the goal of precision medicine—tailoring the best treatment for each cancer patient. Recent conversion between these two fields is enabling better patient data acquisition and improved design of nanomaterials for precision cancer medicine. Diagnostic nanomaterials are used to assemble a patient‐specific disease profile, which is then leveraged, through a set of therapeutic nanotechnologies, to improve the treatment outcome. However, high intratumor and interpatient heterogeneities make the rational design of diagnostic and therapeutic platforms, and analysis of their output, extremely difficult. Integration of AI approaches can bridge this gap, using pattern analysis and classification algorithms for improved diagnostic and therapeutic accuracy. Nanomedicine design also benefits from the application of AI, by optimizing material properties according to predicted interactions with the target drug, biological fluids, immune system, vasculature, and cell membranes, all affecting therapeutic efficacy. Here, fundamental concepts in AI are described and the contributions and promise of nanotechnology coupled with AI to the future of precision cancer medicine are reviewed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adma.201901989

Cites

180 of 180 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AI can optimize multiple aspects of nanoparticle design, including size and charge, drug encapsulation efficiency, interactions with biological membranes, vasculature, biological fluids, and drug release kinetics through machine-learning algorithms and computational models.

    “AI can optimize multiple aspects of nanoparticle design, including nanoparticles’ size and charge, drug encapsulation efficiency, interactions with biological membranes, vasculature, biological fluids, and drug release kinetics through machine-learning algorithms and computational models.342”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [342]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 8

  1. [16]Foquet M Samiee KT Kong X Chauduri BP Lundquist PM Turner SW Freudenthal J Roitman DB Journal of Applied Physics 2008 103 034301
  2. [40]Nair P Alam M Applied physics letters 2006 88 233120 Zhang Z Chan DW Cancer Epidemiology and Prevention Biomarkers 2010 19 2995 PMC4836873 20962299
  3. [64]El-Sayed IH Huang X El-Sayed MA Cancer letters 2006 239 129 16198049 Lu Y Low PS Advanced drug delivery reviews 2012 64 342 12204598
  4. [71]Laeubli H Available from: https://clinicaltrials.gov/ct2/show/NCT03603379?term=Anti-EGFR+immunoliposomes&rank=3 Shi J Kantoff PW Wooster R Farokhzad OC Nature Reviews Cancer 2017 17 20 27834398 PMC5575742
  5. [72]Brannon-Peppas L Blanchette JO Advanced drug delivery reviews 2012 64 206 15350294 Rosenblum D Joshi N Tao W Karp JM Peer D Nature communications 2018 9 1410 PMC5897557 29650952
  6. [79]Baghaei B Saeb MR Jafari SH Khonakdar HA Rezaee B Goodarzi V Mohammadi Y Journal of Applied Polymer Science 2017 134 45145
  7. [95]Rosenberg SA Retrieved from: https://clinicaltrials.gov/ct2/show/record/NCT03480152?term=mRNA&cond=cancer Zhan X Retrieved from: https://clinicaltrials.gov/ct2/show/NCT03468244?term=mRNA&cond=cancer&rank=50 Kulkarni JA Cullis PR Van Der Meel R nucleic acid therapeutics 2018 28 146 29683383
  8. [106]Harrington KJ Mohammadtaghi S Uster PS Glass D Peters AM Vile RG Stewart JSW Clinical Cancer Research 2001 7 243 11234875

Cited by

Sorted by citations

Authors
Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky‐Roitman, J., Lammers, T., & Schroeder, A.
Affiliations
  • Technion – Israel Institute of Technology (IL)
  • Tel Aviv University (IL)
  • Universitätsklinikum Aachen (DE)
Corresponding author
Schroeder, Avi
Venue
Advanced Materials
Publisher
Wiley
Published
2019-07-09
Volume
32
Issue
13
Pages
e1901989-e1901989
ISSN
  • 0935-9648 (ISSN-L)
  • 1521-4095
OpenAlex
W2957366757
Cited by
496
References
179
Citations by year
2026: 69 · 2025: 113 · 2024: 111 · 2023: 70 · 2022: 54 · 2021: 49 · 2020: 29 · 2019: 1
FWCI
2.67
Type
journal article
Language
en
Open access
Locations
  • Advanced Materials (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
Funders
  • European Research Council (STG‐2015‐680242)
  • Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology
  • Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, Technion-Israel Institute of Technology
  • Ministry of Economy (52752)
  • Ministry of Science and Technology, Israel (3‐11878)
  • Israel Science Foundation (1778/13, 1421/17)
  • Israel Cancer Association (2015‐0116)
  • German-Israeli Foundation for Scientific Research and Development (I‐2328‐1139.10/2012)
  • FP7 Science in Society (908049)
  • Phospholipid Research Center
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanotechnology research and applications
Keywords
artificial intelligence, nanotechnology, precision oncology, nanomedicine, intratumoral heterogeneity, interpatient heterogeneity, machine learning classification
MeSH terms
Animals, Artificial Intelligence, Humans, Neoplasms, Drug Delivery Systems, Computational Biology, Nanotechnology, Nanostructures, Nanomedicine, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review